PHILADELPHIA, June 13, 2016 /PRNewswire/ -- The Intellectual Property & Science business of Thomson Reuters, the world's leader in intelligent information for businesses and professionals, announced the winners of the Allicense 2016 Breakthrough Awards. Bristol-Myers Squibb's acquisition of Cardioxyl Pharmaceuticals took top honors in the Mergers and Acquisitions (M&A) category, and the partnership between Gilead Sciences and Galapagos won the award for top Biopharmaceutical Licensing Deal.
The awards— determined by public vote—were presented on Wednesday, June 8 at Allicense in San Francisco, California. Allicense is an annual event that brings together the industry's leading minds from the Pharmaceutical, Biotech and Financial communities to tackle today's most relevant issues and shape the future of deal-making. Allicense is the only event where 200+ qualified dealmakers focus exclusively on key issues facing the industry.
"Our acquisition of Cardioxyl is a perfect example of how business development can help diversify our portfolio for long-term growth," said Paul Biondi, senior vice president, head of business development, Bristol-Myers Squibb. "This deal builds on Bristol-Myers Squibb's rich history of business development in cardiovascular disease, biotech, venture capital and biopharma working together with a common goal to deliver transformational medicines for patients. We are pleased to be recognized by the BioPharma community for impactful deal-making and honored to be given this recognition."
"We are honored to receive this award. Our deal with Gilead for filgotnib is transformational for our Company and I am pleased that it is recognized by the industry as well," said Onno van de Stolpe, chief executive officer, Galapagos. "We look forward to bring this JAK1-selective inhibitor in inflammatory diseases together with Gilead to patients all over the world."
Thomson Reuters analysts used Thomson Reuters Recap—the premier analysis tool for biopharmaceutical business deal-making —to examine hundreds of deals negotiated in 2015 to nominate five contenders in both award categories, backed by data in Cortellis Competitive Intelligence. The nominations were then put to a public vote by the biopharmaceutical community to accurately identify the most influential deals executed in 2015.
"The winners of this year's Breakthrough Awards are a testament to the power of strategic partnerships, licensing and capital markets activity in shaping the direction of the biopharmaceutical development pipeline," said Richard Harrison, chief scientific officer, Intellectual Property & Science, Thomson Reuters. "Heart failure affects over 5 million Americans each year and the novel therapies represented in this deal can have a profound effect on alleviating the disease. I'd like to personally congratulate Bristol-Myers Squibb, Cardioxyl Pharmaceuticals, Gilead Sciences and Galapagos for their commitment to pioneering new scientific breakthroughs."
Thomson Reuters is the world's leading source of news and information for professional markets. Our customers rely on us to deliver the intelligence, technology and expertise they need to find trusted answers. The business has operated in more than 100 countries for more than 100 years. For more information, visit www.thomsonreuters.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/thomson-reuters-recognizes-bristol-myers-squibbcardioxyl-and-gileadgalapagos-as-top-biopharma-deals-of-the-year-300283731.html
SOURCE Thomson Reuters